Belgium's UCB on Wednesday said it has agreed to acquire Zogenix for as much as $1.9 billion in a deal centered around an epilepsy drug the California-based biotech brought to market 18 months ago.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,